JB
Zevra Therapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| MIPLYFFA® (arimoclomol) | Niemann-Pick disease type C (NPC) | Filed (EU) |
| OLPRUVA® | Urea Cycle Disorders (UCDs) | Approved |
| Celiprolol | Vascular Ehlers-Danlos Syndrome (VEDS) - COL3A1 positive | Phase 3 |
| KP1077 | Idiopathic Hypersomnia / Sleep Disorders | Phase 2 |
Leadership Team at Zevra Therapeutics
NF
Neil F. McFarlane
President & Chief Executive Officer
JR
Justin Renz
Chief Financial Officer
JS
Joshua Schafer
Chief Commercial Officer
AQ
Adrian Quartel, M.D., FFPM
Chief Medical Officer
RW
Rahsaan W. Thompson
Chief Legal Officer, Secretary and Compliance Officer
AP
Alison Peters
Chief People Officer
TH
Tanya Hayden
Senior Vice President, Chief of Staff
GO
Gerald Orehostky
Senior Vice President, Regulatory Affairs and Quality
CM
Christopher M. Lauderback, PhD
Senior Vice President, Manufacturing
TS
Timothy Sangiovanni, CPA
Senior Vice President, Finance and Corporate Controller